When America pays what Europe pays, Europe waits longer for new medicines

Melonie WarfelChief Commercial Officer, SwishX·9 min read
Contents
  1. Introduction
  2. Most favored nation went from executive order to industry standard in about fifteen months
  3. The policy has a real point, and the UK shows it can work
  4. Without a deal, a reference country is a risk to be managed
  5. Launch sequencing is now a pricing decision
  6. The second-order effects land on evidence, teams and content
  7. What global leaders should decide before the next launch

The US now ties what it pays for new drugs to the lowest price in other wealthy countries, and the first effect is showing up in Europe's launch queue. Launch order has become a pricing decision, and global teams need to plan for it before the next Phase 3 readout.

For decades, the order in which a new medicine reached the world's markets was mostly a regulatory and reimbursement question. Since May 2025 it has become a pricing question. When the United States insists on paying no more than the lowest price in other wealthy countries, each of those countries becomes a possible ceiling on the US price, and the cheapest way to avoid a low ceiling is not to launch there yet.

That is the argument of this essay in one line. Under international reference pricing, the first price set anywhere becomes the price everywhere, so companies now sequence launches by price rather than by approval date, and Europe is where that shows up first. The early numbers are noisy and part of the trend predates the policy, but the direction is clear enough that global launch, market access and brand teams should plan for it now.

These are my views, not legal advice.

Most favored nation went from executive order to industry standard in about fifteen months

Executive Order 14297, signed on May 12, 2025, told HHS to give manufacturers most favored nation price targets and to pursue rulemaking and importation if they did not make progress. On July 31 the White House sent letters to 17 manufacturers with four asks: give Medicaid MFN prices, never offer another developed country a better price on a new medicine than the US gets, sell directly to patients at no more than the best developed-country price, and accept that the administration would use trade policy to help companies raise prices abroad, provided the extra revenue went into lower US prices.

The deals followed quickly. Pfizer signed first on September 30, 2025, and said it would get a three-year grace period from planned pharmaceutical tariffs. AstraZeneca, EMD Serono, Eli Lilly and Novo Nordisk followed within six weeks, nine more companies signed on December 19, and Regeneron became the seventeenth in April 2026. On August 31 the White House added nine mid-sized companies and said the 26 manufacturers now cover 89% of the branded market. The public terms are the same each time: MFN prices for Medicaid, MFN prices on new launches, direct-to-patient discounts through TrumpRx, and repatriation of increased foreign revenue. The detailed terms are confidential.

Formal rules sit alongside the deals. CMS announced a voluntary Medicaid model, GENEROUS, in November 2025. It finalized the GLOBE model for Medicare Part B on September 30, 2026, tying rebates on some Part B drugs to prices in 19 countries from January 2027, but cut it back so far that CMS expects only four manufacturers to be in scope, with projected federal savings down from $11.9 billion in the proposal to about $440 million. PhRMA sued to block it on October 7. The Part D companion, GUARD, is still under review at OMB. As of October 2026, the regulations are the backstop. The deals are where the pricing actually happens.

The policy has a real point, and the UK shows it can work

Before arguing about consequences, the intent deserves a fair hearing. A 2024 RAND study using 2022 data found US manufacturer prices for brand-name drugs were 422% of prices in 33 OECD comparison countries. EFPIA, Europe's own industry body, puts the US at 74.1% of global sales of new active substances against 15.6% for Europe. Whatever you think of the politics, Americans are paying for most of the return on new medicines, and the complaint that other wealthy countries ride on that is one that European drug company chief executives, Novartis's Vas Narasimhan among them, now make in public.

The design is cleverer than it looks. MFN does not cut the US price by decree. It makes a low price abroad expensive for the company, which then has every reason to push the foreign government. Lilly said as much in August 2025 when it raised the UK private-market price of Mounjaro's highest dose from £122 to £330 a month, arguing that prices paid in markets like Europe need to rise so that US prices can fall.

Britain is the proof that the pressure can move a government. Talks on the UK's VPAG rebate scheme collapsed in August 2025. Within weeks MSD scrapped a £1 billion London research centre, AstraZeneca paused a £200 million expansion in Cambridge, and Lilly paused its London Gateway Labs. On December 1 the UK agreed a deal with the US: a 25% increase in the net price the NHS pays for new medicines from April 2026, a NICE threshold raised to £25,000 to £35,000 per QALY, the VPAG repayment rate held at or below 15%, and medicines spending rising from 0.3% to 0.6% of GDP by 2036. In return the UK got zero tariffs on pharmaceuticals into 2029 and a US commitment that a lowest-in-basket UK price would not anchor the Medicaid MFN price. If the goal was to make Europe pay more, this is what success looks like.

Without a deal, a reference country is a risk to be managed

Most of the 19 countries in the GLOBE basket have no such arrangement. For a company that has promised MFN prices on its new launches, a price agreed in Copenhagen or Madrid is no longer only a Danish or Spanish revenue decision. It can become a floor under the US price in a market that, by EFPIA's figures, is worth several times all of Europe combined for a new drug.

Companies are acting on that. Amgen withdrew Repatha from Denmark earlier this year, and a Health Affairs Forefront analysis in May read it as a collision with US reference pricing, since Denmark's confidential tender prices sit in the baskets. Under Amgen's MFN deal, the same drug is offered to US cash buyers through TrumpRx at $239 a month, against a $573 list price. Insmed postponed the German launch of Brinsupri, approved in the EU in November 2025, citing uncertainty over US pricing. Bristol Myers Squibb said it would launch Cobenfy in the UK at the US list price of about $1,850 a month, and said it could halt the launch if NICE does not recommend it. AstraZeneca's Pascal Soriot told the Financial Times in June that the company could have to hold back new medicines from the UK and Europe unless governments pay more.

The aggregate numbers point the same way. GlobalData counted about 35% fewer new launches across Europe in the ten months after the executive order than in the ten months before, 37% fewer in the six countries named in the GENEROUS basket and 43% fewer across the European markets referenced by GLOBE and GUARD. Brands with at least one pack withdrawn rose 43%. In June, EU health ministers asked the European Commission to study whether the policy is delaying launches.

I want to be careful here, because the honest answer is that we do not yet know how much of this is MFN. GlobalData itself found that about 92% of products approved in 2025 launched first in the US, which was already the norm. EFPIA's latest access report, published in May, puts the median wait for a new medicine in Europe at 532 days and finds 49% of recent medicines unavailable, but its cohort was approved between 2021 and 2024, before the policy existed. Europe was already waiting. MFN gives companies a reason to make the wait longer, and a ready explanation when they do.

Launch sequencing is now a pricing decision

Here is the model I would put in front of any global launch team. Sort every market by two questions: whether it sits in a basket the US references, and whether it will pay a price you can live with as a benchmark for the US. Those two answers give four kinds of market, and each gets a different plan.

Markets in the basket that will pay go early, alongside the US or just behind it. That is exactly the position the UK bought with its deal. Basket markets that will not pay wait, negotiate or get skipped, which is where Denmark landed for Repatha. Markets outside the basket can be planned on their own logic and may move up the queue, because a price there does not travel. The last group, outside the basket and unable to pay much, is where access programs and tiered pricing belong, as they did before.

The benchmark is not a single number, which matters more than most people think. CMS adjusts foreign prices for national wealth, and its own assessment puts Germany's purchasing power at 83% of the US level and Spain's and the Czech Republic's at 64%. A lower price in a poorer country is not automatically a problem. The work is to know, before you agree to any price, exactly how it will be adjusted and compared, which means the pricing team has to sit in the room where launch order is decided rather than being told about it afterward.

If the IRA put a clock on the US launch, MFN puts a map on the global one. Together they mean that the first approval, the first indication and the first price all carry consequences for years and across borders. The first price you set is the only one you fully get to choose.

The second-order effects land on evidence, teams and content

Evidence comes first. If a company will only launch in Europe at a price close to the US benchmark, its evidence has to justify that price to NICE, to Germany's benefit assessment and, for cancer medicines and advanced therapies since January 2025, to the EU's joint clinical assessment, which extends to orphan drugs in 2028 and all new medicines by 2030. That means comparisons against European standards of care, planned into Phase 3 rather than bolted on after US approval. A trial designed only for FDA and US payers is now a trial designed to delay Europe.

Global teams change shape too. Affiliate general managers used to own their launch timing within a global plan. Now a global price committee effectively holds a veto over every launch in the basket, and some country teams will spend years preparing for a launch that keeps moving. Medical affairs carries more of the load in the waiting markets, through MSLs, scientific exchange and early access programs, and in France the health authority has reported a sharp fall in early access applications.

Content is the effect almost nobody is planning for. A single global core story works when launches land within a year of each other. When Europe launches two or three years after the US, it launches into a different label, a different competitor set and a newer evidence base, and the core story written for the US launch has aged. The answer is not one global deck or twenty local ones. It is a core set of approved claims with versions for each label and market, and localization that checks claims against the local label, not only the language.

As for winners and losers, US Medicaid and cash-pay patients gain, at least on paper. European patients lose time. The hardest choices fall on smaller biotechs with one product, because a single European price can define their whole business. And markets outside the reference baskets may, for once, find themselves earlier in the queue.

What global leaders should decide before the next launch

Decide the price corridor and the launch sequence before the Phase 3 readout, not after US approval. Map every country your MFN agreement and the GLOBE basket reference, model the adjusted benchmark each one implies, and make launch order a decision that pricing, market access and the global brand lead sign together.

Build the European evidence package for the price you intend to charge, not the price you expect to be offered. Plan the comparators, endpoints and health economic models that NICE and the joint clinical assessment will ask for while the trial is still being designed.

Prepare an honest public answer for every market where you choose to wait. Governments are now tracking this explicitly: the UK arrangement includes an annual review of company launch behaviour in the UK. Saying nothing reads as withholding medicine, and the headlines will be written either way.

Treat the global story as a library rather than a deck, with claims versioned by label and market, so that a launch two years later starts from current evidence rather than from the old one.

Then watch five things: the PhRMA challenge to GLOBE, GUARD at OMB, the European Commission's study for health ministers, the UK's VPAG replacement due by January 2029, and whether any other European government decides the UK's trade was worth copying. For a generation the hard question in a global launch was where to go first. Now it is where to price first, because that price will follow the medicine everywhere it goes.

Filed underPerspectives

Keep reading

All articles

Want to see Magic Studio on your brand?

Video, visual aids, ads, approved email and web, made from your approved claims and ready for MLR review.